Adicet Bio (ACET) said Tuesday the US Food and Drug Administration has granted fast track designation to ADI-001, a CD20-targeted experimental medicine for...
Adicet Bio (ACET) has an average rating of buy and price targets ranging from $21 to $35, according to analysts polled by Capital IQ. (MT Newswires covers...
Adicet Bio (ACET) has an average rating of buy and price targets ranging from $21 to $35, according to analysts polled by Capital IQ. (MT Newswires covers...
Adicet Bio (ACET) on Tuesday filed a shelf registration statement for the potential sale of up to $500 million of its securities from time to time. The...
| Address | 200 Clarendon Street Boston, Massachusetts 02116 |
| Phone | +1.650.503.9095 |
| Number of Employees | N/A |
| Recent SEC Filing | 06/21/2022 8-K |
| President, CEO, Secretary & Director | Chen Schor |
| Chief Financial Officer | Brian Nicholas Harvey |
| Chief Medical Officer & Senior Vice President | Francesco Galimi |
| Chief Technology Officer | Donald Healey |
| Price Open | $13.85 |
| Previous Close | $14.36 |
| 52 Week Range | $6.25 - 21.17 |
| Market Capitalization | $574.5 M |
| Shares Outstanding | 40.0 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | 08/11/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.15 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | -93.18% |
| Return on Equity | -13.61% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
